TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+0.75%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.44B
AUM Growth
+$2.44B
(-4%)
Cap. Flow
-$52.5M
Cap. Flow
% of AUM
-2.15%
Top 10 Holdings %
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$43.6M |
| 2 |
Humana
HUM
|
$23.9M |
| 3 |
Eli Lilly
LLY
|
$20.7M |
| 4 |
Illumina
ILMN
|
$18.9M |
| 5 |
Abbott
ABT
|
$15.8M |
Top Sells
| 1 |
McKesson
MCK
|
$43.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$23.3M |
| 3 |
UnitedHealth
UNH
|
$23M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
$21.7M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$19.4M |
Sector Composition
| 1 | Healthcare | 96.9% |
| 2 | Real Estate | 1.86% |
| 3 | Industrials | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
UnitedHealth
UNH
$281B
| $138M | 5.67% | 274,046 -45,464 | -14% | -$23M |
|
|
2
Johnson & Johnson
JNJ
$427B
| $128M | 5.24% | 783,779 +267,127 | +52% | +$43.6M |
|
3
Amgen
AMGN
$155B
| $117M | 4.79% | 518,869 -29,549 | -5% | -$6.66M |
|
4
Gilead Sciences
GILD
$140B
| $100M | 4.1% | 1,622,165 -28,600 | -2% | -$1.76M |
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $90.7M | 3.71% | 313,403 -47,828 | -13% | -$13.8M |
|
|
6
Eli Lilly
LLY
$657B
| $77.8M | 3.18% | 240,578 +64,146 | +36% | +$20.7M |
|
|
7
Abbott
ABT
$231B
| $76.5M | 3.13% | 791,051 +163,759 | +26% | +$15.8M |
|
|
8
Regeneron Pharmaceuticals
REGN
$61.5B
| $75.1M | 3.08% | 109,062 -33,802 | -24% | -$23.3M |
|
9
AbbVie
ABBV
$372B
| $70.7M | 2.89% | 526,842 -40,000 | -7% | -$5.37M |
|
10
AstraZeneca
AZN
$248B
| $69.8M | 2.86% | 1,273,193 +148,452 | +13% | +$8.14M |
|
11
Bristol-Myers Squibb
BMY
$96B
| $62.5M | 2.56% | 879,476 +96,741 | +12% | +$6.88M |
|
12
Cigna
CI
$80.3B
| $58.5M | 2.39% | 210,731 +37,625 | +22% | +$10.4M |
|
|
13
Illumina
ILMN
$15.8B
| $56.3M | 2.3% | 294,943 +98,896 | +50% | +$18.9M |
|
|
14
Humana
HUM
$36.5B
| $54.8M | 2.24% | 113,004 +49,210 | +77% | +$23.9M |
|
15
Pfizer
PFE
$141B
| $49.5M | 2.03% | 1,132,103 | – | – |
|
16
Merck
MRK
$210B
| $47.5M | 1.95% | 552,122 | – | – |
|
17
Thermo Fisher Scientific
TMO
$186B
| $47.5M | 1.95% | 93,705 -3,900 | -4% | -$1.98M |
|
|
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $45.4M | 1.86% | 734,353 -141,736 | -16% | -$8.77M |
|
19
Molina Healthcare
MOH
$9.8B
| $39.4M | 1.61% | 119,535 +14,450 | +14% | +$4.77M |
|
20
Stryker
SYK
$150B
| $39.2M | 1.6% | 193,528 -32,150 | -14% | -$6.51M |
|
21
Biogen
BIIB
$19.4B
| $38.8M | 1.59% | 145,439 +9,800 | +7% | +$2.62M |
|
22
Moderna
MRNA
$9.37B
| $37.2M | 1.52% | 314,924 -13,600 | -4% | -$1.61M |
|
23
Danaher
DHR
$147B
| $32.2M | 1.32% | 124,556 | – | – |
|
24
Boston Scientific
BSX
$156B
| $30.8M | 1.26% | 795,215 | – | – |
|
25
Alnylam Pharmaceuticals
ALNY
$58.5B
| $28.7M | 1.17% | 143,214 +14,800 | +12% | +$2.96M |
|